Investors

Investors

Company Profile

Arena is a biopharmaceutical company focused on discovering and developing novel, small molecule drugs. We are currently directing our activities and resources primarily on:

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

Events & Presentations
Annual Report and Proxy Statement
Date Title and Summary
Toggle Summary Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Initiation of Etrasimod ELEVATE UC 52 and Olorinab CAPTIVATE Trials
- Etrasimod initiation of the Phase 3 ELEVATE UC 52 global trial in ulcerative colitis (UC) - Olorinab initiation of the Phase 2 CAPTIVATE clinical trial in abdominal pain associated with irritable bowel syndrome (IBS) - Multiple first- or best-in-class drug candidates, skilled leadership team and
Toggle Summary Arena Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on August 7
SAN DIEGO , July 31, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2019 financial results and provide a corporate update on Wednesday, August 7, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live